Aim: The optimal antibiotic regimen for preterm premature rupture of membrane (pPROM) is still unclear. This study aimed to determine the effects of ampicillin-sulbactam (SBT/ABPC) and azithromycin (AZM) on the incidence of bronchopulmonary dysplasia (BPD). Methods: This retrospective study included women with singleton gestations and a diagnosis of pPROM between 22 and 27 weeks of gestation. In patients presenting with a high risk of intra-amniotic infection between January 2011 and May 2013, piperacillin or cefmetazole + clindamycin (regimen 1 group; n = 11) was administered, whereas SBT/ABPC and AZM (regimen 2 group; n = 11) were administered in patients presenting a similar risk between June 2013 and May 2016. Results: The incidence of moderate or severe infant BPD in the regimen 2 group was significantly lower than that in the regimen 1 group, even when adjusted for gestational age at the time of rupture of membrane, with an odds ratio (95% confidence interval) of 0.02 (1.8 × 10
Introduction
The occurrence of preterm premature rupture of membrane (pPROM) before week 28 of gestation is the leading cause of very or extremely low infant birth weight. There is a very high incidence of shortto long-term complications in such cases, with the fetal's normal development being hindered.
Respiratory disorders are the most common of these complications, with the progression to bronchopulmonary dysplasia (BPD) occurring in cases where the disorder is prolonged. In particular, it has been reported that there is a connection between the longterm prognosis and cases of moderate or greater BPD, wherein the need for oxygen administration extends beyond the 36-week postmenstrual age [1] [2] [3] ; therefore, it is extremely important to prevent the onset of this condition. In addition to premature birth, intra-amniotic infection, particularly Ureaplasma infection, has been linked to the onset of BPD. 4 Cases where pPROM occurs before week 28 of gestation are susceptible to the onset of both these conditions, and they are also strongly related to the onset of BPD.
Currently, ampicillin (ABPC) + erythromycin (EM) is the most common antimicrobial agent administered in cases of pPROM. [5] [6] [7] [8] [9] However, since EM has a very low rate of passage to the uterus, it cannot be expected to treat Ureaplasma infection, and its ability to prevent BPD is thought to be limited. 10 It has also been reported that ampicillin-sulbactam (SBT/ABPC) increased the time from pPROM to labor, with fewer complications, than ABPC alone. 11 Until now, many studies, including randomized controlled trials, have reported on the usefulness of administering azithromycin (AZM) to preterm infants as a means to prevent the onset of BPD. [12] [13] [14] [15] A metaanalysis concluded that the administration of AZM to preterm infants significantly reduced the incidence of BPD with a risk ratio of 0.86 (95% confidence interval (CI): 0.77-0.97). 16 In animal experiments, it has been reported that, along with reduced lung tissue infection, maternal administration of AZM for intraamniotic infection caused by Ureaplasma resulted in prolonged gestation and elimination of bacteria. [17] [18] [19] In humans, AZM also has a high rate of passage into the uterus, and particularly into the placental tissue and membrane, and its effectiveness for treating Ureaplasma infection may aid in prolonging gestation. 20, 21 However, the optimal antibiotic regimen for pPROM has not been clearly established yet. Thus, the study aimed to determine the effects of SBT/ABPC and AZM on the incidence of BPD, and to investigate whether changing the antibiotic regimens prolonged the length of the pregnancy.
Methods
Women with singleton gestations admitted to the NHO Saga Hospital between January 2011 and May 2016 with the diagnosis of pPROM (22-27 weeks of gestation) were included in this retrospective study. The exclusion criteria were as follows: (i) patients who were in labor, required labor induction, required emergent cesarean section after rupture of membrane (ROM) was diagnosed or admitted due to ROM;
(ii) unavailability of perinatal outcome data; (iii) with multiple fetal anomalies; and (iv) the patients who were considered as low-risk patients and who received only ABPC + EM or ABPC + clarithromycin (CAM) during the study period.
Rupture of membrane was diagnosed by a previous history of watery vaginal discharge and a combination of the following tests: confirming leakage of amniotic fluid from cervical os or vaginal pooling of amniotic fluid, and a positive IGFBP-1 test through a sterile speculum examination.
At our hospital, from January 2011 to May 2013, we administered ABPC + EM in low-risk patients with pPROM and administered piperacillin (PIPC) + clindamycin (CLDM) in high-risk patients (regimen 1). However, to enhance the therapeutic effects of the treatment, we switched to regimen 2 in June 2013, administering ABPC and CAM in low-risk patients, and administering SBT/ABPC and AZM in high-risk patients.
Regimen 1 group
Patients with maternal C-reactive protein (CRP) of less than 0.12 mg/dL or greater than 0.12 mg/dL, but with amniotic fluid leukocyte count of less than 100 000/cm 3 , were considered as low-risk patients and administered ABPC and EM (48 h of parenteral antibiotics followed by 5 days of oral amoxicillin and EM). If the amniotic fluid leukocyte count was above 100 000/cm 3 , the patient was considered as high risk, and PIPC or cefmetazole + CLDM was administered.
Amniotic fluid was sampled by amniocentesis every 2-3 days. Leukocyte count determination, direct smear examination, as well as aerobic, anaerobic and family Mycoplasmataceae tests were performed. Adjustments to the antimicrobial agent and administration periods were determined according to the test results. In patients who tested positive for family Mycoplasmataceae, genetic tests were performed to identify Ureaplasma and Mycoplasma.
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Regimen 2 group
Between June 2013 and May 2016, the amniotic fluid was sampled by amniocentesis in all cases and interleukin (IL)-6 in the amniotic fluid was measured. Patients whose IL-6 was less than 9300 pg/mL were considered low risk and ABPC (48 h of parenteral antibiotics followed by 5 days of oral amoxicillin + CAM) was administered for 7 days, whereas those whose IL-6 was higher than 9300 pg/mL were considered as high-risk patients, and 1.5 g of SBT/ABPC was administered intravenously every 6 h along with AZM 500 mg (intravenous) every 24 h.
As in the earlier phase, IL-6 levels in the amniocentesis samples were measured, and changes to the antimicrobial agents and to the administration periods were made.
AZM concentrations remain high in the placental tissue for a relatively long period; thus, AZM was stopped after 3 days of administration, and if the amniotic fluid cultures a week later did not test negative for mycoplasma, then the medication was resumed for another 3 days.
All procedures followed were in accordance with the ethical standards of the Institutional Review Board of the NHO Saga Hospital (Ref no. 29-6) and with the Helsinki Declaration of 1964 and later versions. A written informed consent was obtained from all patients before the amniocentesis and before participating in the study.
All analyses were performed using JMP (version 11). Unpaired t-test was used to evaluate maternal age, gestational age at delivery, birth weight, days of continuous positive airway pressure (CPAP), and hospital days if normally distributed. Nonparametric data were compared using Wilcoxon tests. The chisquared test or Fisher's exact probability test was used to compare all categorical variables. Regarding factors that showed significant differences in univariate analysis, multiple regression analysis or multiple logistic regression analysis was performed using the pPROM week number as the adjustment factor.
Results
Characteristics of the study population
Twenty-two patients with pPROM were included in this study. Table 1 shows the demographic and clinical characteristics of the study population. There were no significant differences in any of the factors between the two groups; however, compared with the regimen 2 group, the pPROM week number of the regimen 1 group was earlier (P = 0.04).
Pregnancy outcomes of the study population Table 2 shows the pregnancy outcomes. In the univariate analysis, the parturition week number for the regimen 2 group was significantly higher; however, there was no significant difference found when adjusted for gestational age at the time of ROM.
Neonatal outcomes of the study population Table 3 shows the neonatal outcomes. The incidence of BPD, including moderate-to-severe BPD, in the regimen 2 group was significantly low, even when adjusted for the pPROM week number, and the odds ratio was also low. Even when adjusted for pPROM week number, the number of days of mechanical ventilation was significantly less in the regimen 2 group. Univariate analysis showed that the number of days of antimicrobial agent administration was significantly shorter; however, there was no significant difference observed when adjusted for the pPROM week number.
Discussions
This retrospective study shows that the administration of AZM or SBT/ABPC as antimicrobial agents in patients with pPROM occurring from gestational weeks 22 to 27 resulted in a reduced incidence of BPD, including moderate-to-severe BPD, and reduced number of days of mechanical ventilation.
In our department, amniotic fluid sampling was performed every 2-3 days. The second amniocentesis was necessary to decide whether to continue the pregnancy or to either continue or change the antibiotic therapy, depending on the result of the first amniotic fluid culture and the change in the amniotic fluid IL-6 level between the first and second amniocentesis. If the patient has a decreased IL-6 level and is generally in good health, despite being diagnosed with intraamniotic infection, we recommend that the patient should continue the pregnancy and undergo antibiotic therapy and amniotic fluid sampling every 2-3 days to rule out re-exacerbation. If patients have not been diagnosed with intra-amniotic infection, they undergo amniotic fluid sampling every 2-3 days to ensure the early detection of new infections. Given that microorganisms invade the intra-amniotic cavity immediately during the premature rupture of membrane, maternal temperature, maternal fever, and WBC and CRP levels may be late indicators of infections.
In this study, estimated fetal body weight (EFBW) at ROM was not included in the characteristics of the study population because the birth weight in both groups was not significantly different after adjusting for gestational age at the time of ROM. The EFBW at the time of ROM in the regimen 1 group was 610 g (range: 461-687 g), which was significantly lower than that in the regimen 2 group (868 g, range: 619-1160 g); however, no significant differences were found when adjusting for gestational age at the time of ROM. The coefficient of correlation for the EFBW at the time of ROM in the regimen 1 and 2 groups was 0.91. Thus, the EFBW was not considered as an independent factor. ABPC + EM is the recommended antimicrobial agent for patients with pPROM. [5] [6] [7] [8] [9] However, in a study examining blood cultures of 27 children with early onset neonatal sepsis (EONS) as well as placental amniotic fluid cultures of 1133 patients where intra-amniotic infection was suspected, more than half were found to have either gram negative or anaerobic bacteria derived from the intestinal tract, and many of these are not susceptible to ABPC. 23 Regarding the effectiveness of EM and CLDM, a study analyzing the amniotic fluid cultures of 46 patients with pPROM found that amniotic fluid bacterial cultures were positive in seven patients (Ureaplasma in six patients, Mycoplasma in one patient). Ceftriaxone, CLDM and EM were administered for 10-14 days to these patients; however, as six of the seven patients were also positive in a second test of amniotic fluid bacterial cultures, the effectiveness of EM and CLDM has not been verified. 10 In an animal experiment, Ureaplasma parvum was introduced into the amniotic fluid of rhesus monkeys, followed by intravenous administration of AZM for 10 days to determine the effectiveness of maternal AZM administration. Compared with the control, the AZM group had higher rates of bacterial Ureaplasma eradication in the amniotic fluid, and fetal and placental tissues, longer length of gestation, and lesser degrees of acute and chronic fetal lung tissue inflammation. 18 In humans, the passage of AZM to the placental tissue is also satisfactory. Regarding the pharmacokinetics of the maternal administration of AZM, the amount of AZM in fetal blood is less than 50% that of the mother, which is also similar in the amniotic fluid. The concentration in the placental tissue becomes very high and remains highly concentrated for over 3 days. 20 Thus, only a relatively small 63.6 (7/11) 63.6 (7/11) 1.00 - †Regimen 1 group: piperacillin and clindamycin for high-risk patient; ‡Regimen 2 group: ampicillin-sulbactam and azithromycin for high-risk patient; §P-value after adjusting for gestational age at the time of rupture of membrane; ¶Median (interquartile range). Latency: antibiotic-to-delivery interval. amount of AZM is transferred to the fetus in regimen 2, and it may be possible to maintain a high concentration of AZM in the placental tissue for about 7 days.
However, there are a few reports on the effectiveness of the maternal administration of AZM in humans. A retrospective study 24 from 2009 to 2013 of 168 patients with pPROM occurring at week 24 to week 34 of gestation compared one group administered ABPC + EM to another group administered ABPC + AZM. The number of days from antimicrobial agent administration to parturition, the frequency of chorioamnionitis, and the frequency of sepsis, respiratory distress syndrome, and infant mortality were examined. The results showed that 1 day of oral administration of AZM had similar effects as 7 days of EM administration. As for the intravenous or continuous administration of AZM, its superiority to EM has not been reported yet.
In the present study, the frequency of moderate-tosevere infant BPD was significantly lower in the regimen 2 group than in the regimen 1 group. This decrease was significant even when adjusting for gestational age at the time of ROM, with the odds ratios being very low for both the regimen 2 and regimen 1 groups. This finding was important for the choice of antibiotics when pPROM occurred especially in late mid-trimester because BPD frequently developed during this period. The days of mechanical ventilation were also reduced significantly, and, considering the absence of difference in high frequency oscillation and continuous positive airway pressure days between the groups, the probability that this decrease in the incidence of BPD was due to a change in neonatal breathing management is thought to be low. There was no difference observed in the number of days from maternal administration of antimicrobial agents to parturition. In the regimen 2 group, Ureaplasma was eradicated or IL-6 in the amniotic fluid was suppressed in 4/7 cases. Rather than prolonging the gestation, it is thought that the reduction in the transmission of Ureaplasma to the infant and reduction in fetal pulmonary disorders lead to the decrease in BPD incidence. In the current study, the suppression of Ureaplasma infection by the administration of AZM is thought to be the main mechanism of BPD incidence reduction; however, the suppression of infection and inflammation via the control of ABPCresistant bacterial infection by SBT/ABPC may also play a role.
Our results showed that the administration of regimen 2 reduced the incidence of moderate-to-severe BPD, resulting in the normal physical growth and development of the fetus and reduced number of days with regard to artificial respirator use. This regimen can help optimize the utilization of the limited equipment of the neonatal intensive care unit. The prevention of BPD onset by neonatal AZM administration has already been reported, but the results of a meta-analysis combining three studies showed a risk ratio of 0.86 and 95% CI of 0.77-0.97 with an AZM dose of 10 mg/kg/day for 7 days, followed by 1-6 weeks at 5 mg/kg/day. 16 Our present study found that maternal AZM administration reduced BPD incidence, and that the fetus was exposed to relatively low levels of AZM; therefore, maternal administration may be the most useful. Regarding the safety of maternal AZM administration, the human pregnancy data do not suggest an embryo-fetal risk of developmental toxicity from AZM. 25 AZM is widely used for the treatment of chlamydial or gonococcal infection, and as antibiotic prophylaxis before cesarean delivery. [26] [27] [28] The current study had several limitations. There is a possibility of bias in the transition of obstetrics management, such as the introduction of amniotic fluid puncture to distinguish the low-risk patients from the high-risk patients. Major changes to neonatal management were not observed during the 5-year observation period of this study; however, minor changes cannot be negated. It is already known that prematurity is strongly related to the onset of BPD, and sufficient attention must be paid to prematurity when investigating BPD incidence. In this study, the pPROM onset week number in the regimen 1 group was earlier than that in the regimen 2 group. Although we confirmed the significance of BPD incidence after adjusting for gestational age at the time of ROM, the possibility that the earlier pPROM onset week number in the regimen 1 group has affected the results cannot be completely discounted. The diagnosis of BPD is based on the presence or absence of oxygen administration, and there is a possibility that such administration may be influenced by the subjective judgment of the attending physician. In the future, it will be necessary to evaluate BPD frequency using diagnosis that has included an objective index, such as the challenge test.
In conclusion, this retrospective observational study, utilizing historical control, found that administering SBT/ABPC and AZM as antimicrobial agents reduced the incidence of BPD, including the incidence of moderate-to-severe BPD, in very early pPROM, and reduced the number of days of mechanical ventilation. In patients with pPROM between 22 and 27 weeks of gestation, administration of SBT/ABPC and AZM may improve the perinatal outcomes.
